Search Results - "Goodman, Aaron M."

Comparing Physician and Artificial Intelligence Chatbot Responses to Patient Questions Posted to a Public Social Media Forum by Ayers, John W, Poliak, Adam, Dredze, Mark, Leas, Eric C, Zhu, Zechariah, Kelley, Jessica B, Faix, Dennis J, Goodman, Aaron M, Longhurst, Christopher A, Hogarth, Michael, Smith, Davey M

“…The rapid expansion of virtual health care has caused a surge in patient messages concomitant with more work and burnout among health care professionals…”
Get more information

Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers by Goodman, Aaron M, Kato, Shumei, Bazhenova, Lyudmila, Patel, Sandip P, Frampton, Garrett M, Miller, Vincent, Stephens, Philip J, Daniels, Gregory A, Kurzrock, Razelle

“…Immunotherapy induces durable responses in a subset of patients with cancer. High tumor mutational burden (TMB) may be a response biomarker for PD-1/PD-L1…”
Get full text

Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era by Goyal, Gaurav, Heaney, Mark L., Collin, Matthew, Cohen-Aubart, Fleur, Vaglio, Augusto, Durham, Benjamin H., Hershkovitz-Rokah, Oshrat, Girschikofsky, Michael, Jacobsen, Eric D., Toyama, Kazuhiro, Goodman, Aaron M., Hendrie, Paul, Cao, Xin-xin, Estrada-Veras, Juvianee I., Shpilberg, Ofer, Abdo, André, Kurokawa, Mineo, Dagna, Lorenzo, McClain, Kenneth L., Mazor, Roei D., Picarsic, Jennifer, Janku, Filip, Go, Ronald S., Haroche, Julien, Diamond, Eli L.

“…Erdheim-Chester disease (ECD) is a rare histiocytosis that was recently recognized as a neoplastic disorder owing to the discovery of recurrent activating MAPK…”
Get full text

STK11 alterations in the pan-cancer setting: prognostic and therapeutic implications by Krishnamurthy, Nithya, Goodman, Aaron M., Barkauskas, Donald A., Kurzrock, Razelle

“…STK11 is an important tumour suppressor gene reported to confer immunotherapy resistance in non–small-cell lung cancers (NSCLC) especially in the presence of…”
Get full text

MHC-I genotype and tumor mutational burden predict response to immunotherapy by Goodman, Aaron M, Castro, Andrea, Pyke, Rachel Marty, Okamura, Ryosuke, Kato, Shumei, Riviere, Paul, Frampton, Garrett, Sokol, Ethan, Zhang, Xinlian, Ball, Edward D, Carter, Hannah, Kurzrock, Razelle

“…Immune checkpoint blockade (ICB) with antibodies inhibiting cytotoxic T lymphocyte-associated protein-4 (CTLA-4) and programmed cell death protein-1 (PD-1) (or…”
Get full text

Radiation-associated cutaneous mastocytosis: a case report and review of the literature by Aaron Trando, Austin, Karen M, Hinds, Brian, Jeong, Ah-Reum, Goodman, Aaron M

Get full text

Appearance of New Cutaneous Superficial Basal Cell Carcinomas during Successful Nivolumab Treatment of Refractory Metastatic Disease: Implications for Immunotherapy in Early Versus Late Disease by Cohen, Philip R, Kato, Shumei, Goodman, Aaron M, Ikeda, Sadakatsu, Kurzrock, Razelle

“…Metastatic basal cell carcinoma may be treated with hedgehog pathway inhibitors, including vismodegib and sonidegib. However, patients can demonstrate…”
Get full text

Intra-patient stability of tumor mutational burden from tissue biopsies at different time points in advanced cancers by Pham, Timothy V, Goodman, Aaron M, Sivakumar, Smruthy, Frampton, Garrett, Kurzrock, Razelle

“…Tumor mutational burden (TMB) may be a predictive biomarker of immune checkpoint inhibitor (ICI) responsiveness. Genomic landscape heterogeneity is a…”
Get full text

Genomic landscape of advanced basal cell carcinoma: Implications for precision treatment with targeted and immune therapies by Goodman, Aaron M, Kato, Shumei, Cohen, Philip R, Boichard, Amélie, Frampton, Garrett, Miller, Vincent, Stephens, Philip J, Daniels, Gregory A, Kurzrock, Razelle

“…Metastatic basal cell cancer (BCC) is an ultra-rare malignancy with no approved therapies beyond Hedgehog inhibitors. We characterized the genomics, tumor…”
Get full text

Systematics of the Arboreal Neotropical ‘thorellii’ Clade of Centruroides Bark Scorpions (Buthidae) and the Efficacy of Mini-Barcodes for Museum Specimens by Goodman, Aaron M., Prendini, Lorenzo, Esposito, Lauren A.

“…Fragmented and degraded DNA is pervasive among museum specimens, hindering molecular phylogenetics and species identification. Mini-barcodes, 200–300-base-pair…”
Get full text

Rosai-Dorfman-Destombes (RDD) disease presenting as palindromic rheumatism by Haghighat Jahromi, Amin, Goodman, Aaron M, Hoh, Carl K

“…Rosai-Dorfman-Destombes (RDD) disease, is a rare proliferative and inflammatory disorder of non-Langerhans cell histiocytes. We report a 35-year-old woman, who…”
Get full text

Tumor Infiltrating Lymphocyte Expression of PD-1 Predicts Response to Anti-PD-1/PD-L1 Immunotherapy by Bevins, Nicholas J, Okamura, Ryosuke, Montesion, Meagan, Adashek, Jacob J, Goodman, Aaron M, Kurzrock, Razelle

“…Many studies have focused on the role of programmed death receptor ligand 1 (PD-L1) expression in predicting immunotherapy outcomes. Limited clinical data are…”
Get full text

Higher tumor mutational burden and PD-L1 expression correlate with shorter survival in hematologic malignancies by Jeong, Ah-Reum, Trando, Aaron H, Thomas, Sean D, Riviere, Paul, Sakowski, Patrick J, Sokol, Ethan S, Goodman, Aaron M, Kurzrock, Razelle

“…The prognostic implications of tumor mutational burden (TMB) and programmed death ligand 1 (PD-L1) expression are poorly studied in hematologic malignancies…”
Get full text

Age-Adjusted Schedules of Venetoclax and Hypomethylating Agents to Treat Extremely Elderly Patients with Acute Myeloid Leukemia by Lee, Aaron M., Goodman, Aaron M., Mangan, James K.

“…Acute myeloid leukemia (AML) is associated with particularly poor outcomes in the elderly population, in whom the disease is most prevalent. BCL-2 has been…”
Get full text

Characteristics of measurable residual disease assessment in myeloma: a review of clinical trials from 2015–2020 by Van Oekelen, Oliver, Birrer, Nicole, Wesson, William, Galate, Vincent L., Cliff, Edward R. Scheffer, Goodman, Aaron M., Abdallah, Al-Ola, Chakraborty, Rajshekhar, Prasad, Vinay, Mohyuddin, Ghulam Rehman

Get full text

Case Report: Multiple Chromosomal Translocations Including Novel CIITA-CREBBP Fusion and Mutations in a Follicular Lymphoma by Wang, Huan-You, Sokol, Ethan S, Goodman, Aaron M, Feldman, Andrew L, Mulroney, Carolyn M

“…The pathogenesis of follicular lymphoma is a multi-step process, in which chromosomal translocation between immunoglobulin heavy chain (IgH) and anti-apoptotic…”
Get full text

Relationship between tumor mutational burden and maximum standardized uptake value in 2-[18F]FDG PET (positron emission tomography) scan in cancer patients by Haghighat Jahromi, Amin, Barkauskas, Donald A., Zabel, Matthew, Goodman, Aaron M., Frampton, Garret, Nikanjam, Mina, Hoh, Carl K., Kurzrock, Razelle

“…Purpose Deriving links between imaging and genomic markers is an evolving field. 2-[ 18 F]FDG PET/CT ( 18 F-fluorodeoxyglucose positron emission…”
Get full text

Autoimmune HLA Alleles and Neoepitope Presentation Predict Post-Allogenic Transplant Relapse by Castro, Andrea, Goodman, Aaron M., Rane, Zachary, Talwar, James V., Frampton, Garrett M., Morris, Gerald P., Lippman, Scott M., Zhang, Xinlian, Kurzrock, Razelle, Carter, Hannah

“…ABSTRACT Introduction Allogeneic hematopoietic stem cell transplantation (allo-HSCT) can cure patients with high-risk myelodysplastic syndromes (MDS) and acute…”
Get full text

Overtreatment of multiple myeloma and its precursor states: de-escalation is an urgent need in clinical practice and trials by Mohyuddin, Ghulam Rehman, Goodman, Aaron M.

“…Certain subsets of patients with multiple myeloma or its precursor conditions are overtreated with current approaches to therapy. Herein, we highlight several…”
Get full text

Ineligible for transplant, but eligible for intensive quadruplet therapy—The value of ‘add-on’ trials for vulnerable patient populations by Mohyuddin, Ghulam Rehman, Goodman, Aaron M.

Get full text